Powerful perspectives

Industry Insight
Scientific innovation in uveal melanoma

Industry Insight
Opportunities and challenges in oncology immunotherapy

Industry Insight
Reflections from our CEO

Industry Insight
Pancreatic cancer – our commitment to scientific advances

Industry Insight
A bold new era in global cancer drug discovery

Industry Insight
A note from our CEO

Industry Insight
Realising the potential of autotaxin therapy in cancer

Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors

Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All articles

iOnctura expands pipeline and receives development grant from Health Holland and KWF

iOnctura awarded UK’s MHRA innovation passport for entry into innovative licensing and access pathway (ILAP)

iOnctura announces publication of pioneering research describing the unique biological features of roginolisib

iOnctura provides development update on first-in-class semi-allosteric PI3Kδ inhibitor program

iOnctura awarded EUR17.5 million funding from the EIC accelerator for clinical development of novel pancreatic cancer therapy

iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289

iOnctura expands Advisory Board

iOnctura to present at ASCO IOA-244 showing highly promising impact on overall survival for patients with metastatic and refractory uveal melanoma

iOnctura to present at ASCO encouraging Phase Ib refractory uveal melanoma data for first semi-allosteric PI3Kδ inhibitor, IOA-244

iOnctura data at AACR demonstrates unique mechanism of action for clinical stage autotaxin inhibitor IOA-289

iOnctura to present preclinical data on its clinical stage autotaxin inhibitor, IOA-289, at AACR

Looking for media
resources?